NCT04538040 - Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 19, 2019

Primary Completion Date

November 11, 2021

Study Completion Date

November 11, 2021

Conditions

HIV-1-infection

Interventions

DRUG

Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch

Safety and efficacy of switching from rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir, to bictegravir/emtricitabine/tenofovir alafenamide in combination with doravirine in male, 45+ year old subjects. The study will also include secondary outcomes of quality of life (QOL) and weight changes.

Trial Locations (1)

94114

SFOMG Private Practice, San Francisco